In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 27, No. 15_suppl ( 2009-05-20), p. e16013-e16013
Kurzfassung:
e16013 Background: Malignant transformation (MT) is a rare phenomenon characterized by a neoplastic somatic differentiation within a GCT. Little is known concerning its clinical implications. An international registry (INTera Project) has been established to collect all past and new cases worldwide. Methods: Patients (pts) with a MT within GCT have been retrospectively identified from registries of contributing Institutions. Significant clinical and pathological data have been collected and data files gathered at the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan. Results: 47 pts have been identified as well as a variety of 12 histologies. 25 pts had MT in primary tumor: 14 of them had no metastases (11 underwent primary retroperitoneal lymph-node dissection - RPLND), and 11 underwent chemotherapy (CT) ± surgery due to metastatic disease. All 14 pts with no metastases remain disease-free (DF) following a median follow-up (f-up) of 72 months (2–236+ months). 6 of 11 pts undergoing chemotherapy remain disease-free following a median f-up of 155 months (8–297+). 22 pts had MT in metastases only and 20 of them are evaluable. Following CT, 7 underwent radical surgery and 5 of them remain DF following a median f-up of 77 months (19–166+ months), while 13 could not undergo radical removal of disease, and 3 of them have been rescued by further CT and are DF at 37+, 41+ and 79+ months. So far, all 14 pts with no metastases as well as 7/9 (78%) who had radical removal of disease are alive and DF versus only 7/22 pts (32%) who could not receive a radical excision of residual masses. Median disease-free survival of pts with MT in primary only versus distant sites only was 54 (0–326+) and 2.5 (0–166+) months respectively (p=0.064 - at Log-rank test). No relevant outcome differences have been observed according to histology. Conclusions: Ongoing INTera project is a collaborative effort of MT case- collection worldwide. Stage of disease and radical surgery seem to associate with outcome. The growing number of cases and a centralized pathology review would help to increase knowledge on this rare disease. No significant financial relationships to disclose.
Materialart:
Online-Ressource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/jco.2009.27.15_suppl.e16013
Sprache:
Englisch
Verlag:
American Society of Clinical Oncology (ASCO)
Publikationsdatum:
2009
ZDB Id:
2005181-5
Bookmarklink
